How Disease-Modifying Therapies Are Advancing Type 1 Diabetes Research

Developing new treatments for Type 1 diabetes requires a structured approach that begins with basic discovery research and moves through multiple stages before reaching patients. JDRF supports this entire pipeline—from early laboratory work to advanced clinical trials—while also advocating for government funding and partnering with for-profit organizations to accelerate progress.

JDRF's disease-modifying therapy portfolio advances through three complementary approaches. First, active clinical trials funded by JDRF are testing new approaches in real patients and moving the broader field forward. Second, the organization is investing in ways to improve how future clinical trials are designed and conducted, building greater momentum for upcoming research. Third, JDRF is strategically funding new projects aimed at filling gaps in our current knowledge—work that will support the next generation of disease-modifying therapies.

Disease-modifying therapies represent an important research direction because they aim to change the natural course of Type 1 diabetes, rather than simply managing blood sugar after diagnosis. By funding research across discovery, development, and clinical testing, JDRF is working to expand the options available to people living with or at risk for Type 1 diabetes. This multi-stage approach helps ensure that promising laboratory discoveries eventually reach patients who need them.

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.